Sarepta Therapeutics Inc (NASDAQ:SRPT) CEO Purchases $2,000,133.64 in Stock

Sarepta Therapeutics Inc (NASDAQ:SRPT) CEO Douglas S. Ingram purchased 16,252 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was bought at an average cost of $123.07 per share, for a total transaction of $2,000,133.64. Following the acquisition, the chief executive officer now owns 424,405 shares in the company, valued at approximately $52,231,523.35. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of SRPT stock traded down $1.97 during mid-day trading on Monday, hitting $124.14. 1,710,700 shares of the stock traded hands, compared to its average volume of 1,249,193. Sarepta Therapeutics Inc has a twelve month low of $95.21 and a twelve month high of $165.87. The stock has a market capitalization of $9.38 billion, a price-to-earnings ratio of -22.74 and a beta of 2.01. The stock’s 50-day simple moving average is $146.13. The company has a current ratio of 12.17, a quick ratio of 11.15 and a debt-to-equity ratio of 0.35.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($3.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.08) by ($2.66). Sarepta Therapeutics had a negative net margin of 165.52% and a negative return on equity of 56.64%. The firm had revenue of $94.67 million for the quarter, compared to analyst estimates of $91.05 million. During the same quarter last year, the business posted ($1.67) earnings per share. The firm’s revenue for the quarter was up 28.8% compared to the same quarter last year. Equities analysts forecast that Sarepta Therapeutics Inc will post -4.42 earnings per share for the current year.

Several analysts have weighed in on SRPT shares. ValuEngine downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. BTIG Research set a $190.00 target price on Sarepta Therapeutics and gave the company a “buy” rating in a research note on Wednesday, April 17th. William Blair reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research note on Friday. Evercore ISI reaffirmed a “buy” rating and set a $200.00 target price on shares of Sarepta Therapeutics in a research note on Thursday. Finally, BidaskClub downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 3rd. Two analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. Sarepta Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $208.29.

Several hedge funds have recently modified their holdings of the company. Evolution Wealth Advisors LLC acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter worth $25,000. Trust Co. of Vermont grew its holdings in shares of Sarepta Therapeutics by 2,125.0% in the 2nd quarter. Trust Co. of Vermont now owns 178 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 170 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter worth $32,000. Lindbrook Capital LLC acquired a new position in shares of Sarepta Therapeutics in the 1st quarter worth $35,000. Finally, Coastal Investment Advisors Inc. grew its holdings in shares of Sarepta Therapeutics by 57.4% in the 2nd quarter. Coastal Investment Advisors Inc. now owns 425 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 155 shares during the last quarter. Institutional investors own 94.72% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Further Reading: Why does the United States have a lingering trade deficit?

Insider Buying and Selling by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.